Alliancebernstein L.P. Has $683.32 Million Position in IQVIA Holdings Inc. $IQV

Alliancebernstein L.P. grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 1.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,597,572 shares of the medical research company’s stock after purchasing an additional 41,643 shares during the quarter. Alliancebernstein L.P. owned about 2.11% of IQVIA worth $683,323,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in IQV. Eubel Brady & Suttman Asset Management Inc. bought a new stake in IQVIA in the third quarter valued at $14,278,000. Eagle Rock Investment Company LLC boosted its position in shares of IQVIA by 33.6% during the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock worth $8,800,000 after purchasing an additional 11,657 shares in the last quarter. OPTIMAS CAPITAL Ltd acquired a new stake in shares of IQVIA in the 3rd quarter valued at about $4,008,000. Amundi raised its stake in IQVIA by 46.3% during the 2nd quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after buying an additional 405,250 shares during the period. Finally, EDENTREE ASSET MANAGEMENT Ltd acquired a new stake in IQVIA in the third quarter valued at approximately $7,368,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on IQV. Evercore reaffirmed an “outperform” rating and set a $225.00 target price on shares of IQVIA in a research report on Thursday, February 5th. UBS Group lowered their price objective on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research note on Friday, March 6th. BMO Capital Markets set a $250.00 target price on shares of IQVIA in a report on Friday, February 6th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Buy” and an average target price of $229.13.

IQVIA Stock Performance

Shares of IQV stock opened at $164.78 on Friday. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a 50-day moving average of $201.58 and a 200-day moving average of $206.80. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company has a market cap of $27.96 billion, a P/E ratio of 20.96, a P/E/G ratio of 1.59 and a beta of 1.39.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.